Precision Medicine News and Research

RSS

First Round Table Meeting on Metabolomics & Diabetes takes place in Vienna

Metabolomic biomarker research is a young research area that carries great hopes for both medicine and the nutritional sciences, particularly for the early detection of genetically determined diseases.

14 Jan 2011

Vanderbilt, Scripps Research form partnership to open new institute

The Scripps Research Institute and Vanderbilt University have formed a partnership to advance science at the interface of chemistry and medicine, the institutions announced today.

14 Jan 2011

DNAVision purchases 4 of Life Technologies' NGS platforms

DNAVision, one of European leading genetic analysis service providers, is pleased to announce the purchase of four next-generation sequencing platforms from Life Technologies, including two latest 5500xl SOLiD™ Systems.

13 Jan 2011

Study identifies over 30 breast cancer gene targets involved in drug resistance to chemotherapy

A new study conducted by Josh LaBaer's research team in the Biodesign Institute at Arizona State University has pinpointed more than 30 breast cancer gene targets ---including several novel genes---that are involved in drug resistance to a leading chemotherapy treatment.

11 Jan 2011

LabCorp to market On-Q-ity's circulating tumor cell platform

On-Q-ity, a next-generation oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, today announced a strategic alliance with Laboratory Corporation of America Holdings® (LabCorp). LabCorp will market On-Q-ity's novel and proprietary circulating tumor cell (CTC) platform to the biopharma industry to greatly accelerate and improve the cancer drug discovery and development process.

10 Jan 2011

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Plexxikon, Inc., announced today that it has signed an agreement with Genentech to co-promote PLX4032 (RG7204) in the United States. PLX4032, an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation, is being tested in late-stage clinical trials for the treatment of metastatic melanoma.

7 Jan 2011

Signal Genetics, Caris Life Sciences announce new agreement to commercialize MyPRS tool

Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.

6 Jan 2011

JAX, Tufts University unveil new mammalian genetics track for PhD students

The Jackson Laboratory, Sackler School of Graduate Biomedical Sciences at Tufts, and Tufts University School of Medicine have unveiled a new mammalian genetics track for PhD students. The joint track offers students in-depth research and training at both JAX and Tufts.

6 Jan 2011

IRIS ships 3,000th iQ200 Automated Urine Microscopy Analyzer to Sarasota Memorial Hospital

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, has shipped its 3,000th iQ200Automated Urine Microscopy Analyzer.

5 Jan 2011

Patients with over expression of P-Rex1 protein are more likely to develop cancer metastasis

Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients.

23 Dec 2010

Itamar Medical, Roche enter development agreement for EndoPAT device

Itamar Medical, the leader in non-invasive vascular health diagnostics, announced today that an agreement has been signed with Roche by which Itamar will develop an EndoPAT device designated for use with animal models, enabling pre-clinical studies examining the efficacy of various compounds in the early stage of drug development essential for later stage development in humans.

20 Dec 2010

23andMe project aims at validating highly scalable pharmacogenomics research

23andMe has launched a project funded by the National Institutes of Health which is aimed at validating 23andMe's highly-scalable platform for pharmacogenomics research. The company received $190,000 in stimulus funding from the American Recovery and Reinvestment Act of 2009 for "Web-based Phenotyping for Genome-Wide Association Studies of Drug Response" from NIH's National Human Genome Research Institute.

17 Dec 2010

Study: Biomarkers may aid in early diagnosis of breast cancer

Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.

17 Dec 2010

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Researchers at UT Southwestern Medical Center have discovered sets of genes active in cancer cells and normal tissue that predict survival time and potential new treatments for patients with non-small cell lung cancer.

15 Dec 2010

Silicon Biosystems' newly formed subsidiary to commercialize DEPArray technology platform

Silicon Biosystems, S.p.A., a provider of specialized molecular and cell biology technology, today announced that it has formed a U.S. subsidiary operation, Silicon Biosystems, Inc., to be headquartered in San Diego, California. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company's DEPArray™ technology platform.

13 Dec 2010

Caliper to acquire CRi for $20.0 million

Caliper Life Sciences, Inc., a leading provider of products and services for drug discovery research, today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research & Instrumentation, Inc. (CRi) for approximately $20.0 million, including net debt. CRi's patented preclinical and tissue-based multiplexed analysis systems will expand Caliper's life sciences tools portfolio, particularly as it bridges into clinical research, pathology and clinical market applications.

10 Dec 2010

Personalized medicine advocates push for better reimbursement system

The U.S. reimbursement for diagnostic tests is outdated and inhibits the development of more personalized tests for patients, according to a report released Tuesday by the Personalized Medicine Coalition.

9 Dec 2010

ChipDX validates genetic signature for early-stage colon cancer

ChipDX LLC, a New York-based online molecular diagnostics and personalized medicine company, discovered and validated a genetic signature for early-stage colon cancer and is developing an online screening application to enable clinicians to more accurately identify risk of recurrence. In the study, published in the December issue of the British Journal of Cancer, ChipDX demonstrates how the 163-gene signature stratifies colon cancer patients into high- and low-risk groups for recurrence with greater accuracy than current methods.

8 Dec 2010

New tool for predicting disease course in children with Crohn's disease

A new study published in the journal Inflammatory Bowel Diseases develops a computer based visual tool that can be used in “real time” to show pediatric Crohn’s disease (CD) patients’ predicted disease course and how this might be influenced by different treatment options.

6 Dec 2010

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Elsevier, the world's leading publisher of scientific, technical and medical information, announced today that its highly respected Cancer Genetics and Cytogenetics journal is changing its title to Cancer Genetics and has named Dr. Jaclyn A. Biegel as editor-in-chief.

6 Dec 2010